Flecainide is primarily known by its brand name, Tambocor [1].
What is Tambocor used to treat?
Tambocor is a medication used to treat certain types of serious heart rhythm disorders, specifically paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia [1]. It is also used for the long-term management of ventricular arrhythmias [1].
How does Tambocor work?
Tambocor belongs to a class of drugs known as Class Ic antiarrhythmics. It works by blocking sodium channels in the heart muscle, which slows down electrical conduction and helps to restore a normal heart rhythm [1].
When does the Tambocor patent expire?
The original patents for flecainide have long since expired, allowing for the availability of generic versions. DrugPatentWatch.com tracks patent information, and for flecainide, the key patent protections have lapsed, leading to generic market entry [2].
Are there generic versions of Tambocor available?
Yes, due to patent expirations, generic versions of flecainide are available. These generic alternatives offer the same active ingredient and are typically more affordable than the brand-name Tambocor [2].
What are the risks associated with Tambocor?
Tambocor can have significant side effects and risks, including an increased risk of mortality in patients with non-life-threatening ventricular arrhythmias [1]. It is also associated with proarrhythmic effects, meaning it can cause new or worsened heart rhythm disturbances. Due to these risks, Tambocor is generally reserved for patients with disabling supraventricular arrhythmias or significant ventricular arrhythmias who have not responded to other treatments [1].
How does flecainide compare to other antiarrhythmics?
Flecainide is a potent sodium channel blocker with a Class Ic classification. Other antiarrhythmic drug classes, like beta-blockers (Class II) or potassium channel blockers (Class III), work through different mechanisms and have different risk profiles. Flecainide's primary indication is for symptomatic supraventricular arrhythmias and certain ventricular arrhythmias, but its use in post-myocardial infarction patients with ventricular arrhythmias is generally contraindicated due to increased mortality risk [1].
Where can I find more information on flecainide patents?
Information regarding drug patents, including those for flecainide, can be found on specialized patent tracking websites like DrugPatentWatch.com [2].
What side effects are patients concerned about with flecainide?
Patients and healthcare providers are concerned about flecainide's potential to cause new or worsened arrhythmias (proarrhythmic effect), as well as other side effects like dizziness, nausea, headache, and visual disturbances [1].
Who manufactures Tambocor?
Tambocor is manufactured by 3M Pharmaceuticals [1]. Generic versions are produced by various pharmaceutical companies.
What is the typical dosage for Tambocor?
Dosage for Tambocor is individualized based on the patient's condition and response. Treatment usually begins with a low dose and is gradually increased as needed and tolerated [1].
Sources:
1. Tambocor Prescribing Information.
2. DrugPatentWatch.com